![Ran Weinstock](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Ran Weinstock
Keine laufenden Positionen mehr
Karriereverlauf von Ran Weinstock
Ehemalige bekannte Positionen von Ran Weinstock
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Bioblast Pharma Ltd.
![]() Bioblast Pharma Ltd. BiotechnologyHealth Technology Bioblast Pharma Ltd. operates as a clinical development-stage biopharmaceutical company. It focuses on the identification, licensing, acquisition, development and commercialization of drugs for rare and ultra-rare genetic diseases. The company also focuses on diseases with severe and debilitating manifestations, where the unmet medical need is clear, the biological mechanism of action is understood, and for which there is no satisfactory treatment. Its product candidates include Protein Stabilizing, Read-through, and Mitochondrial Protein Replacement Platforms. The company was founded by Dalia Megiddo and Ehud Moshe Gilboa on January 22, 2012 and is headquartered in Tel Aviv, Israel. | Direktor/Vorstandsmitglied | 31.07.2018 | - |
Independent Dir/Board Member | 31.07.2018 | - |
Ausbildung von Ran Weinstock
Tel-Aviv University | Undergraduate Degree |
Netanya Academic College | Graduate Degree |
Bar-Ilan University | Graduate Degree |
Statistik
International
Israel | 5 |
Operativ
Graduate Degree | 2 |
Director/Board Member | 1 |
Independent Dir/Board Member | 1 |
Sektoral
Consumer Services | 4 |
Health Technology | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 1 |
---|---|
Bioblast Pharma Ltd.
![]() Bioblast Pharma Ltd. BiotechnologyHealth Technology Bioblast Pharma Ltd. operates as a clinical development-stage biopharmaceutical company. It focuses on the identification, licensing, acquisition, development and commercialization of drugs for rare and ultra-rare genetic diseases. The company also focuses on diseases with severe and debilitating manifestations, where the unmet medical need is clear, the biological mechanism of action is understood, and for which there is no satisfactory treatment. Its product candidates include Protein Stabilizing, Read-through, and Mitochondrial Protein Replacement Platforms. The company was founded by Dalia Megiddo and Ehud Moshe Gilboa on January 22, 2012 and is headquartered in Tel Aviv, Israel. | Health Technology |
- Börse
- Insiders
- Ran Weinstock
- Erfahrung